The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer

Patients' clinical factors and genetics factors such as anaplastic lymphoma kinase (ALK) fusion variants and BIM (Bcl-2-like 11) polymorphism were reported to be associated with clinical outcome in crizotinib-treated advanced non-small cell lung cancer (NSCLC). However, the results were still c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yen-Ting, Liu, Yi-Nan, Shih, Jin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768009/
https://www.ncbi.nlm.nih.gov/pubmed/31608224
http://dx.doi.org/10.3389/fonc.2019.00880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768009/
https://www.ncbi.nlm.nih.gov/pubmed/31608224
http://dx.doi.org/10.3389/fonc.2019.00880

Ejemplares similares